# Observational Study of Blinatumomab

> **NCT03117621** · — · COMPLETED · sponsor: **Amgen** · enrollment: 279 (actual)

## Conditions studied

- Blincyto Use in Routine Clinical Practice

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03117621
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-22
- **Primary completion:** 2024-03-20
- **Final completion:** 2024-03-20
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03117621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03117621, "Observational Study of Blinatumomab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03117621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*